Deep Genomics vs Alan

Alan has a disclosed valuation of $5.8B, while Deep Genomics's valuation is not publicly available, making a direct size comparison difficult. Alan employs 500-1000 people.

Alan has raised more in total funding at $750M, compared to Deep Genomics's $180M — a gap of $570M. Combined, the two companies have completed 2 known funding rounds.

Alan leads with an Awaira Score of 83/100, while Deep Genomics sits at 68/100. That 15-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Deep Genomics was founded by Brendan Frey in 2015. Alan was founded by Jean-Charles Samuelian in 2016. Visit each company's profile on Awaira for a full founder biography.

Deep Genomics: Deep Genomics applies deep learning to genetic medicine discovery, using AI models trained on genomic sequence data to predict the functional consequences of genetic variants, identify RNA splicing defects that underlie genetic diseases, and generate novel therapeutic candidates including antisense oligonucleotides and small molecules that correct disease-causing genetic variants. The Toronto company was founded by Brendan Frey, a University of Toronto machine learning professor who collaborated with Geoffrey Hinton on deep learning research.\n\nThe company raised approximately $180 million in venture funding from investors including True Ventures, AlleyCorp, and GV (Google Ventures). Deep Genomics has built an AI drug discovery platform called the AI Workbench that integrates genomic data, disease biology, and AI prediction across the therapeutic discovery pipeline, and has entered a strategic alliance with Agenus to develop cancer treatments using its AI-designed oligonucleotide candidates.\n\nDeep Genomics competes in the AI genetic medicine space against Recursion Pharmaceuticals, Insitro, Exscientia, and gene therapy companies building computational biology capabilities. Its specific focus on RNA biology and oligonucleotide therapeutics, which represent a growing class of approved genetic medicines, differentiates it from platforms focused on small molecule drug discovery or cell therapy. The Toronto University of Toronto AI ecosystem, including connections to the Vector Institute and the Hinton research lineage, provides research credibility and talent access that distinguishes Canadian AI drug discovery from international competitors. Alan: Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources. The Paris company holds full insurance carrier status in France, Belgium, and Spain, operating as a licensed insurer rather than a distribution intermediary.\n\nThe company raised approximately $220 million including a Series D round from investors including Temasek, Coatue, and Index Ventures, reaching a valuation of approximately $1.4 billion. Alan reports over half a million members across its markets, covering employees at several thousand companies including Stripe, Spendesk, and Vinted, with strong growth in SME employer sales driven by its digital-first enrolment and claims experience. The Alan app provides members with health navigation, symptom checking, and AI-generated health content in addition to insurance card and claims management functionality.\n\nAlan competes in the European digital health insurance market against traditional mutuals including Malakoff Humanis and AG2R La Mondiale, as well as digital health insurers including Henner and Oscar Health in the US context. Its vertical integration as a licensed insurer combined with a technology platform differentiates it from insurtechs that distribute existing insurer products through digital channels, giving Alan full control over the member experience and claims economics. The company is considered one of the most significant French technology companies building in regulated financial services.

Deep Genomics got there first, launching in 2015 — that's 1 year of extra runway. Alan didn't arrive until 2016. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Deep Genomics has about 100-500 employees; Alan has about 500-1000. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Deep Genomics and Alan compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.